GeneDx announces leadership transition
WGS•GeneDx appointed Everett Cunningham as CEO and board member, effective on or before December 15, 2026. Katherine Stueland will step down when he joins, remain in an advisory role through January 31, 2027, and the company reaffirmed its full-year 2026 financial guidance.
1. Leadership transition
GeneDx appointed Everett Cunningham as CEO and board member, effective on or before December 15, 2026. Katherine Stueland will step down as CEO and board member when Cunningham joins and remain in an advisory role through January 31, 2027. GeneDx reaffirmed its full-year 2026 financial guidance provided on November 9, 2026.




